$-0.44 EPS Expected for AnaptysBio (ANAB); Hcsf Management Cut Monotype Imaging Holdings In (TYPE) Holding

July 24, 2017 - By Stephen Andrade

Analysts expect AnaptysBio Inc (NASDAQ:ANAB) to report $-0.44 EPS on August, 10.After having $-0.75 EPS previously, AnaptysBio Inc’s analysts see -41.33% EPS growth. The stock increased 0.59% or $0.16 on July 21, reaching $27.26. About shares traded. AnaptysBio Inc (NASDAQ:ANAB) has 0.00% since July 24, 2016 and is . It has underperformed by 16.70% the S&P500.

Hcsf Management Llc decreased Monotype Imaging Holdings In (TYPE) stake by 81.27% reported in 2016Q4 SEC filing. Hcsf Management Llc sold 94,622 shares as Monotype Imaging Holdings In (TYPE)’s stock declined 10.98%. The Hcsf Management Llc holds 21,802 shares with $433,000 value, down from 116,424 last quarter. Monotype Imaging Holdings In now has $776.26M valuation. The stock decreased 0.53% or $0.1 on July 21, reaching $18.65. About shares traded. Monotype Imaging Holdings Inc. (NASDAQ:TYPE) has declined 15.71% since July 24, 2016 and is downtrending. It has underperformed by 32.41% the S&P500.

Among 4 analysts covering Monotype Imaging Holdings (NASDAQ:TYPE), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Monotype Imaging Holdings had 4 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was initiated by Ladenburg Thalmann on Wednesday, May 25 with “Buy”. The stock of Monotype Imaging Holdings Inc. (NASDAQ:TYPE) has “Buy” rating given on Friday, February 12 by Dougherty & Company. Zacks downgraded Monotype Imaging Holdings Inc. (NASDAQ:TYPE) on Tuesday, September 8 to “Sell” rating. The firm earned “Neutral” rating on Thursday, January 12 by JP Morgan.

Investors sentiment decreased to 0.81 in 2016 Q4. Its down 1.35, from 2.16 in 2016Q3. It is negative, as 31 investors sold TYPE shares while 54 reduced holdings. 19 funds opened positions while 50 raised stakes. 37.05 million shares or 1.37% more from 36.54 million shares in 2016Q3 were reported. Oak Associates Oh holds 0.07% or 36,780 shares. Menta has 38,910 shares. Swiss National Bank has 65,200 shares. The Illinois-based Trigran Investments has invested 5.17% in Monotype Imaging Holdings Inc. (NASDAQ:TYPE). 684 were reported by Federated Inc Pa. Parametric Assoc Limited Liability owns 0% invested in Monotype Imaging Holdings Inc. (NASDAQ:TYPE) for 31,507 shares. Panagora Asset Inc invested 0% of its portfolio in Monotype Imaging Holdings Inc. (NASDAQ:TYPE). Huntington Natl Bank owns 713 shares or 0% of their US portfolio. Riverhead Capital Ltd Liability holds 0% in Monotype Imaging Holdings Inc. (NASDAQ:TYPE) or 1,400 shares. Alliancebernstein LP holds 62,352 shares or 0% of its portfolio. Geode Capital Mngmt Ltd Liability Com has invested 0% in Monotype Imaging Holdings Inc. (NASDAQ:TYPE). Ubs Asset Americas holds 27,121 shares or 0% of its portfolio. Confluence Investment Ltd Liability Corp has invested 0.06% of its portfolio in Monotype Imaging Holdings Inc. (NASDAQ:TYPE). Schwab Charles Inv Mgmt has invested 0% in Monotype Imaging Holdings Inc. (NASDAQ:TYPE). Raymond James And has 0% invested in Monotype Imaging Holdings Inc. (NASDAQ:TYPE) for 67,365 shares.

Analysts await Monotype Imaging Holdings Inc. (NASDAQ:TYPE) to report earnings on July, 26. They expect $0.02 EPS, down 90.48% or $0.19 from last year’s $0.21 per share. TYPE’s profit will be $832,450 for 233.13 P/E if the $0.02 EPS becomes a reality. After $0.05 actual EPS reported by Monotype Imaging Holdings Inc. for the previous quarter, Wall Street now forecasts -60.00% negative EPS growth.

Since February 6, 2017, it had 0 insider buys, and 2 selling transactions for $616,860 activity. Another trade for 2,354 shares valued at $47,080 was made by Shaw Douglas J on Monday, March 6.

AnaptysBio, Inc. is a United States biotechnology company. The company has market cap of $555.80 million. The Firm is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. It currently has negative earnings. The Firm develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: